Market Overview

Credit Suisse Maintains on Cubist Pharmaceuticals

Related CBST
UPDATE: Credit Suisse Downgrades Cubist Pharmaceuticals On Execution Risk To Global Expansion Of Hospital Franchise
Wedbush Initiates Coverage On Cubist Pharmaceuticals
Is This Superbug Drug Company Right for Your Portfolio? (Fox Business)

In a report published Friday, Credit Suisse analyst Jason Kantor maintained Outperform on Cubist Pharmaceuticals (NASDAQ: CBST), with a $77.00 price target.

According to the report, CBST previously released Q4 sales and provided a detailed pipeline update, so the call was more about 2014 guidance.

“We believe revenue guidance was conservative and expect Cubicin to easily hit the high end of the range,” the report noted. “More importantly, investor focus in 2014 will be on new products – Tedizolid (PDUFA June 20) and CXA-201 (NDA filing in H1:14). We continue to expect CBST to perform well into these regulatory events, and note that FDA has become increasingly constructive in the field of antibiotics.”

CBST closed Thursday at $75.38.

Latest Ratings for CBST

DateFirmActionFromTo
Nov 2014Credit SuisseDowngradesOutperformNeutral
Nov 2014SunTrust Robinson HumphreyInitiates Coverage onBuy
Nov 2014WedbushInitiates Coverage onNeutral

View More Analyst Ratings for CBST
View the Latest Analyst Ratings

Posted-In: Credit Suisse Jason KantorAnalyst Color Analyst Ratings

 

Related Articles (CBST)

Around the Web, We're Loving...

Get Benzinga's Newsletters